Trial Profile

Clinical study of CYB 004

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CYB 004 (Primary) ; N-N-dimethyltryptamine (Primary)
Indications Anxiety disorders; Psychiatric disorders; Substance-related disorders
Focus Adverse reactions; First in man
Sponsors Cybin

Most Recent Events

08 Jan 2024 Results published in the Cybin Media Release
04 Jan 2024 According to Cybin media release, upcoming data expected to inform next steps for Phase 2.
14 Nov 2023 According to Cybin media release, top-line data from this study is expected around year end 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com